Castillo-Olivares J.,Institute for Animal Health |
Calvo-Pinilla E.,Centro en Investigacion y Sanidad Animal CISA |
Casanova I.,Centro en Investigacion y Sanidad Animal CISA |
Bachanek-Bankowska K.,Institute for Animal Health |
And 5 more authors.
PLoS ONE | Year: 2011
African horse sickness (AHS) is a lethal viral disease of equids, which is transmitted by Culicoides midges that become infected after biting a viraemic host. The use of live attenuated vaccines has been vital for the control of this disease in endemic regions. However, there are safety concerns over their use in non-endemic countries. Research efforts over the last two decades have therefore focused on developing alternative vaccines based on recombinant baculovirus or live viral vectors expressing structural components of the AHS virion. However, ethical and financial considerations, relating to the use of infected horses in high biosecurity installations, have made progress very slow. We have therefore assessed the potential of an experimental mouse-model for AHSV infection for vaccine and immunology research. We initially characterised AHSV infection in this model, then tested the protective efficacy of a recombinant vaccine based on modified vaccinia Ankara expressing AHS-4 VP2 (MVA-VP2). © 2011 Castillo-Olivares et al. Source